Table of Contents
<< Previous Issue | Mar 2021 (Vol: 2021, Issue: 3) | Next Issue >> |
- Section: Licensing
-
Boston Pharmaceuticals In-Licenses Another Two Programmes from GSK
- Section: Mergers & Acquisitions
-
Merck & Co. Hands Over US$1.85 B to Acquire Pandion Therapeutics
-
Takeda Continues Divestment Spree with US$1.3 B Teijin Pharma Deal to Reduce Debt
-
Amgen Spends US$1.9 B on Five Prime to Boost Cancer Pipeline
-
Jazz Pharmaceuticals Bets on Cannabis-based Medicines with US$7.2 B GW Pharmaceuticals Buy
- Section: Opinion & Analysis
-
IQVIA Pharma Deals Review of 2020
- Section: Research & Development
-
Lilly Partners with Rigel on RIPK1 Inhibitors